Company News-宜明昂科英文

2023-03-21

ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting

On March 21, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the company will present the preclinical research data of IMM47 (CD24 antibody

2023-03-17

ImmuneOnco Biopharmaceuticals officially launches phase IIa clinical trial targeting late-stage follicular lymphoma (FL) with IMM0306

On March 17, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that its self-developed bispecific antibody-receptor recombinant protein drug targe

2023-03-15

ImmuneOnco’s Phase Ib/II clinical study of IMM27M combined with PD-1 antibody in patients with advanced solid tumors has been approved by the National Medical Products Administration (NMPA)

On March 15, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the Phase Ib/II clinical study of the Company's self-developed ADCC-enhanc

2023-03-11

Phase II clinical trial of ImmuneOnco Biopharmaceuticals IMM0306 completes first subject enrollment for dosing

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the Phase II clinical trial of ImmuneOnco Biopharmaceuticals bispecific antibody-receptor re

2023-01-29

ImmuneOnco’s Phase Ib/IIa clinical study of IMM0306 combined with lenalidomide in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma has been approved by NMPA

On January 29, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the phase Ib/IIa clinical study of the company's self-developed bispecif